Free Newsletter
Cheap antibiotic could offer breakthrough stroke therapy
Researchers at the University of South Florida say that lab experiments have shown that a cheap, commonly used antibiotic could revolutionize stroke treatment. They say that the use of minocycline immediately after a stroke has the potential of reducing the destruction of brain cells by as much as two thirds.
Injecting the antibiotic after a stroke and for several days afterwards reduces swelling and guards cells from the havoc caused by stroke--where blood clots starve brain cells of vitally needed oxygen. Up to 80 percent of nerve cells survived a stroke in lab and animal tests, twice the rate of survival in cases left untreated. And the antibiotic is already commonly used for acne and arthritis. Stroke is a leading cause of death around the world.
"The safety and therapeutic efficacy of low dose minocycline and its robust neuroprotective effects during acute ischemic stroke make it an appealing drug candidate for stroke therapy," says Dr. Cesar V. Borlongan. "An on-going Phase I clinical study funded by the National Institutes of Health is exploring the use of intravenous minocycline to treat acute ischemic stroke."
- check out the press release
- read the story from the Telegraph
Comments
Wow! Very good news. I don't know what typically happens when a stroke causes damage. However, a change of 67% is really significant. Research is the future of medicine. I cannot help but think of the number of lives that will be helped by this breakthrough. How many more lives will be aided by the next discovery? casino online
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: